Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
| ▸ | PDE8B | O95263 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.30 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.30 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.30 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.30 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.30 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17374147 | 0.87 | HSD11B1 (0.34) | HSD11B1SIRT2PDE8B | |
| SCHEMBL17374411 | 0.77 | HSD11B1 (0.35) | HSD11B1 | |
| SCHEMBL19728281 | 0.77 | NOTUM (0.35) | HSD11B1HCRTR1HCRTR2NOTUMTRPA1 | |
| SCHEMBL24258945 | 0.74 | SIRT2 (0.39) | HSD11B1SIRT2HCRTR1HCRTR2AKR1C4 | |
| SCHEMBL24922866 | 0.73 | SIRT2 (0.47) | SIRT2NOTUMCYP3A4 | |
| SCHEMBL17500082 | 0.72 | MAPT (0.39) | — | |
| SCHEMBL8897496 | 0.72 | HSD17B10 (0.51) | SIRT2NOTUMCYP3A4 | |
| SCHEMBL17374159 | 0.71 | USP30 (0.46) | — | |
| SCHEMBL10263561 | 0.69 | HSD17B10 (0.36) | SIRT2NOTUMCYP3A4 | |
| SCHEMBL24922901 | 0.68 | NOTUM (0.44) | SIRT2NOTUMCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10174014-B2 | Compounds, compositions, and methods for increasing CFTR activity | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20170233379-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. | 2017-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10174014-B2 | Compounds, compositions, and methods for increasing CFTR activity | CFTR, ABCB4, SCNN1B | HSD11B1 3907/4885SIRT2 2600/4885HCRTR1 4365/4885 |
| US-20170233379-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | CFTR, ABCB4, SCNN1B | HSD11B1 3907/4885SIRT2 2600/4885HCRTR1 4365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.